


# Product Information



## REV 5901

Catalog No. 70600

**CAS Registry No.:** 101910-24-1  
**Formal Name:**  $\alpha$ -pentyl-3-(2-quinolinylmethoxy)-benzenemethanol  
**MF:** C<sub>22</sub>H<sub>25</sub>NO<sub>2</sub>  
**FW:** 335.4  
**Purity:**  $\geq$ 98%  
**Stability:**  $\geq$ 1 year at room temperature  
**Supplied as:** A crystalline solid



### Laboratory Procedures

For long term storage, we suggest that REV 5901 be stored as supplied at room temperature. It should be stable for at least one year.

Concentrated stock solutions of REV 5901 can be prepared by dissolving the crystalline solid in an organic solvent such as ethanol, methanol, acetone, DMSO, or acetonitrile. The solubility of REV 5901 in these solvents is approximately 100 mg/ml.

Further dilutions of the stock solution into aqueous buffers or isotonic saline should be made prior to performing biological experiments. Also, ensure that the residual amount of organic solvent is insignificant, since organic solvents may have physiological effects at low concentrations. We do not recommend storing the aqueous solution for more than one day.

REV 5901 has been shown to be a competitive antagonist of peptidoleukotrienes. *In vitro*, it has a K<sub>1</sub> value of 0.7  $\mu$ M vs [<sup>3</sup>H]Leukotriene D<sub>4</sub> (LTD<sub>4</sub>) binding to membranes from guinea pig lung.<sup>1</sup> It is an antagonist of LTC<sub>4</sub>-induced contraction of guinea pig lung parenchymal strips with an IC<sub>50</sub> of 3.6  $\mu$ M and exhibits 91% inhibition of SRS-A mediated bronchospasm in the guinea pig *in vivo* at 10 mg/kg administered intraduodenally.<sup>2</sup> REV 5901 is a potent inhibitor of rat neutrophil 5-lipoxygenase with an IC<sub>50</sub> of 0.12  $\mu$ M.<sup>2</sup> The release of PAF by peritoneal mast cells could be inhibited by REV 5901 in a concentration-dependent manner (IC<sub>50</sub> = 3.9  $\mu$ M).<sup>3</sup>

### References

1. Van Inwegen, R.G., Khandwala, A., Gordon, R., *et al.* REV 5901: An orally effective peptidoleukotriene antagonist, detailed biochemical/pharmacological profile. *J. Pharmacol. Exp. Ther.* **241**, 117-124 (1987).
2. Musser, J.H., Charkraborty, U.R., Sciortino, S., *et al.* Substituted arylmethyl phenyl ethers. 1. A novel series of 5-lipoxygenase inhibitors and leukotriene antagonists. *J. Med. Chem.* **30**, 96-104 (1987).
3. Hogaboam, C.M., Donigi-Gale, D., Shoupe, T.S., *et al.* Platelet-activating factor synthesis by peritoneal mast cells and its inhibition by two quinoline-based compounds. *Br. J. Pharmacol.* **105**, 87-92 (1992).

## Cayman Chemical

**Mailing address**  
1180 E. Ellsworth Road  
Ann Arbor, MI  
48108 USA

**Phone**  
(800) 364-9897  
(734) 971-3335

**Fax**  
(734) 971-3640

**E-Mail**  
custserv@caymanchem.com

**Web**  
www.caymanchem.com

**WARNING: THIS PRODUCT IS FOR LABORATORY RESEARCH ONLY: NOT FOR ADMINISTRATION TO HUMANS. NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.**

#### MATERIAL SAFETY DATA

This material should be considered hazardous until information to the contrary becomes available. Do not ingest, swallow, or inhale. Do not get in eyes, on skin, or on clothing. Wash thoroughly after handling. This information contains some, but not all, of the information required for the safe and proper use of this material. Before use, the user must review the complete Material Safety Data Sheet, which has been sent *via* email to your institution.

#### WARRANTY AND LIMITATION OF REMEDY

Cayman Chemical Company makes **no warranty or guarantee** of any kind, whether written or oral, expressed or implied, including without limitation, any warranty of fitness for a particular purpose, suitability and merchantability, which extends beyond the description of the chemicals hereof. Cayman **warrants only** to the original customer that the material will **meet our specifications at the time of delivery**.

Cayman will carry out its delivery obligations with due care and skill. Thus, in no event will Cayman have **any obligation or liability**, whether in tort (including negligence) or in contract, for any direct, indirect, incidental or consequential damages, even if Cayman is informed about their possible existence.

This limitation of liability does not apply in the case of intentional acts or negligence of Cayman, its directors or its employees.

Buyer's **exclusive remedy** and Cayman's sole liability hereunder shall be limited to a **refund** of the purchase price, or at Cayman's option, the **replacement**, at no cost to Buyer, of all material that does not meet our specifications.

Said refund or replacement is conditioned on Buyer giving written notice to Cayman within thirty (30) days after arrival of the material at its destination. Failure of Buyer to give said notice within thirty (30) days shall constitute a waiver by Buyer of all claims hereunder with respect to said material.

For further details, please refer to our **Warranty and Limitation of Remedy located on our website and in our catalog**.

Copyright Cayman Chemical Company, 01/14/2010